Nutex Health Files 10-K/A Amendment
Ticker: NUTX · Form: 10-K/A · Filed: Apr 30, 2024 · CIK: 1479681
Sentiment: neutral
Topics: 10-K/A, Nutex Health, NUTX, SEC Filing, Financial Report
TL;DR
<b>Nutex Health, Inc. has filed an amended 10-K report for the fiscal year ending December 31, 2023.</b>
AI Summary
Nutex Health, Inc. (NUTX) filed a Amended Annual Report (10-K/A) with the SEC on April 30, 2024. Nutex Health, Inc. filed an amended 10-K for the fiscal year ended December 31, 2023. The company is incorporated in Delaware and headquartered in Houston, Texas. Its common stock trades on the NASDAQ Capital Market under the symbol NUTX. Nutex Health is classified as an accelerated filer and a smaller reporting company. The filing was submitted on April 30, 2024.
Why It Matters
For investors and stakeholders tracking Nutex Health, Inc., this filing contains several important signals. This amended filing provides updated information for the fiscal year 2023, which is crucial for investors to assess the company's current financial health and operational status. As an accelerated filer and smaller reporting company, this filing is important for understanding Nutex Health's regulatory compliance and reporting obligations.
Risk Assessment
Risk Level: medium — Nutex Health, Inc. shows moderate risk based on this filing. The company is an accelerated filer and a smaller reporting company, indicating a need for careful review of its financial disclosures and compliance status.
Analyst Insight
Investors should review the amended 10-K filing for updated financial and operational details of Nutex Health, Inc.
Key Numbers
- 2023-12-31 — Fiscal Year End (Nutex Health, Inc.)
- 2024-04-30 — Filing Date (10-K/A Amendment)
- 001-41346 — SEC File Number (Nutex Health, Inc.)
- 77081 — ZIP Code (Business Address)
Key Players & Entities
- Nutex Health, Inc. (company) — Filer name
- NUTX (company) — Trading Symbol
- NASDAQ Capital Market (company) — Exchange where NUTX is registered
- Delaware (company) — State of incorporation
- Houston, Texas (company) — Business and Mail Address City/State
- 20231231 (date) — Fiscal year end
- 20240430 (date) — Filing date
- Clinigence Holdings, Inc. (company) — Former company name
FAQ
When did Nutex Health, Inc. file this 10-K/A?
Nutex Health, Inc. filed this Amended Annual Report (10-K/A) with the SEC on April 30, 2024.
What is a 10-K/A filing?
A 10-K/A is a amendment to a previously filed annual report, correcting or updating financial statements or disclosures. This particular 10-K/A was filed by Nutex Health, Inc. (NUTX).
Where can I read the original 10-K/A filing from Nutex Health, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Nutex Health, Inc..
What are the key takeaways from Nutex Health, Inc.'s 10-K/A?
Nutex Health, Inc. filed this 10-K/A on April 30, 2024. Key takeaways: Nutex Health, Inc. filed an amended 10-K for the fiscal year ended December 31, 2023.. The company is incorporated in Delaware and headquartered in Houston, Texas.. Its common stock trades on the NASDAQ Capital Market under the symbol NUTX..
Is Nutex Health, Inc. a risky investment based on this filing?
Based on this 10-K/A, Nutex Health, Inc. presents a moderate-risk profile. The company is an accelerated filer and a smaller reporting company, indicating a need for careful review of its financial disclosures and compliance status.
What should investors do after reading Nutex Health, Inc.'s 10-K/A?
Investors should review the amended 10-K filing for updated financial and operational details of Nutex Health, Inc. The overall sentiment from this filing is neutral.
How does Nutex Health, Inc. compare to its industry peers?
Nutex Health operates within the business services sector, providing services to healthcare facilities.
Are there regulatory concerns for Nutex Health, Inc.?
The company is subject to SEC reporting requirements, including the filing of annual reports (10-K) and amendments (10-K/A).
Industry Context
Nutex Health operates within the business services sector, providing services to healthcare facilities.
Regulatory Implications
The company is subject to SEC reporting requirements, including the filing of annual reports (10-K) and amendments (10-K/A).
What Investors Should Do
- Review the full amended 10-K filing for detailed financial statements and management discussion.
- Monitor future filings for any significant changes or updates from Nutex Health.
- Analyze the company's performance and strategic initiatives in the context of its industry.
Key Dates
- 2023-12-31: Fiscal Year End — Reporting period for the 10-K/A filing.
- 2024-04-30: Filing Date — Date the amended 10-K was filed with the SEC.
Year-Over-Year Comparison
This is an amended 10-K filing for the fiscal year ended December 31, 2023, indicating updates or corrections to previously submitted information.
Filing Stats: 4,610 words · 18 min read · ~15 pages · Grade level 10.8 · Accepted 2024-04-30 13:59:41
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value NUTX NASDAQ Capital Marke
Filing Documents
- nutx-20231231x10ka.htm (10-K/A) — 683KB
- nutx-20231231xex31d1.htm (EX-31.1) — 3KB
- nutx-20231231xex31d2.htm (EX-31.2) — 3KB
- 0001558370-24-006236.txt ( ) — 942KB
- nutx-20231231.xsd (EX-101.SCH) — 3KB
- nutx-20231231_lab.xml (EX-101.LAB) — 25KB
- nutx-20231231_pre.xml (EX-101.PRE) — 16KB
- nutx-20231231x10ka_htm.xml (XML) — 8KB
Directors, Executive Officers and Corporate Governance
Item 10. Directors, Executive Officers and Corporate Governance 4
Executive Compensation and Other Information
Item 11. Executive Compensation and Other Information 13
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 25
Certain Relationships and Related Persons Transactions
Item 13. Certain Relationships and Related Persons Transactions 26
Principal Accountant Fees and Services
Item 14. Principal Accountant Fees and Services 27
Exhibits and Financial Statement Schedules
Item 15. Exhibits and Financial Statement Schedules 29
SIGNATURES
SIGNATURES 33 3 Table of Contents PART III
Directors, Executive Officers and Corporate Governance
Item 10. Directors, Executive Officers and Corporate Governance Name Age Position Executive Officers and Directors Thomas T. Vo, M.D., MBA 51 Chief Executive Officer and Chairman of the Board Warren Hosseinion M.D. 52 President and Director Jon C. Bates 54 Chief Financial Officer Michael Chang, M.D. 53 Chief Medical Officer Elisa Luqman, ESQ., MBA 59 Chief Legal Officer (SEC) Pamela Montgomery, R.N., J.D. 67 Chief Legal Officer (Healthcare & Secretary) Mitchell Creem, MHA 66 Independent Director Cheryl Grenas, R.N., M.S.N 64 Independent Director Michael L. Reed, MPH 66 Independent Director Scott J. Saunders 61 Independent Director Kelvin Spears 63 Director Executive Directors Thomas T. Vo, M.D., MBA, Chief Executive Officer, Director and Chairman of the Board Dr. Vo was appointed as the Company's Chief Executive Officer on April 1, 2022 and elected, effective April 1, 2022, as the Chairman of the Board. Since 2010, Dr. Vo has served as the founder and executive officer of affiliates of the Company. Although no longer practicing, Dr. Vo worked as an emergency medicine physician in Houston, Texas, for over twenty years. Between 2008 and 2011, Dr. Vo served as a founder and original partner at the free-standing emergency health company, Neighbors Emergency Center. Since then, Dr. Vo has been involved with the opening of over 40 freestanding emergency departments and micro hospitals. Dr. Vo holds a Bachelor of Science in Life Sciences from Kent State University and received his Doctor of Medicine from North East Ohio Universities College of Medicine. In 2004, Dr. Vo also received his Master of Business Administration from Rice University. The Company believes that Dr. Vo's unique background in the emergency hospital field and proven management experience make him well qualified to serve as a director. Warren Hosseinion, M.D., President and Director Warren Hosseinion, M.D., is the President and a director of th